KT
JAZZ icon

Kanaly Trust’s Jazz Pharmaceuticals JAZZ Stock Holding History

Kanaly Trust’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-7
Closed -$1K – 904
2015
Q3 		$1K Buy
+7
New +$1.21K ﹤0.01% 836

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
HCM
Herndon Capital Management Atlanta, Georgia $659M AUM 22.02% 1-Year Est. Return

Kanaly Trust's JAZZ Position: Q4 2015 in Review

Kanaly Trust sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2015, closing a stake of 7 shares — an estimated $1K sold.

Kanaly Trust first reported a position in JAZZ in Q3 2015 and held it in 1 quarter. The position peaked at $1K in Q3 2015. 345 funds tracked by Wall St. Rank hold JAZZ as of Q4 2015.

  • Kanaly Trust reported no remaining Jazz Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Kanaly Trust sold 7 Jazz Pharmaceuticals shares in Q4 2015, an estimated $1K.
  • Kanaly Trust first reported a position in Jazz Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • Kanaly Trust's Jazz Pharmaceuticals position peaked at $1K in Q3 2015.
  • 345 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2015.

Based on Kanaly Trust's 13F filing for Q4 2015, filed 25 Jan 2016.